Mark Blagden

2.9k total citations
10 papers, 299 citations indexed

About

Mark Blagden is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Blagden has authored 10 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Blagden's work include Lipoproteins and Cardiovascular Health (3 papers), Pain Management and Opioid Use (2 papers) and Bone health and treatments (2 papers). Mark Blagden is often cited by papers focused on Lipoproteins and Cardiovascular Health (3 papers), Pain Management and Opioid Use (2 papers) and Bone health and treatments (2 papers). Mark Blagden collaborates with scholars based in United Kingdom, Germany and Switzerland. Mark Blagden's co-authors include Michael Hopp, Peyman Hadji, O. Löwenstein, Petra Leyendecker, Ricardo Dent, Juraj Payer, Socrates E. Papapoulos, Kathryn Miller, James O’Kelly and Terry McCormack and has published in prestigious journals such as Osteoporosis International, Neurogastroenterology & Motility and European Neuropsychopharmacology.

In The Last Decade

Mark Blagden

10 papers receiving 285 citations

Peers

Mark Blagden

SURGE

OSM

APM

PHEOH

GASTR

Sanath Allampati United States

M. Elena Spain

Rachel Bastiaenen United Kingdom

Xiu‐Qing Yao China

K. Thon Germany

Michał Petelenz Poland

Rachel Houten United Kingdom

So-Hee Lee South Korea

Jane Naberhuis United States

Diana Munteanu Romania

Sanath Allampati United States

Mark Blagden

198 ×1.4

SURGE

8 ×0.1

OSM

12 ×0.2

APM

7 ×0.1

PHEOH

34 ×0.7

GASTR

Citations per year, relative to Mark Blagden Mark Blagden (= 1×) peers Sanath Allampati

Countries citing papers authored by Mark Blagden

Since Specialization

Citations

This map shows the geographic impact of Mark Blagden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Blagden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Blagden more than expected).

Fields of papers citing papers by Mark Blagden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Blagden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Blagden. The network helps show where Mark Blagden may publish in the future.

Co-authorship network of co-authors of Mark Blagden

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Blagden. A scholar is included among the top collaborators of Mark Blagden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Blagden. Mark Blagden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

McCloskey, Eugène, Mark Blagden, Bernard Cortet, et al.. (2022). Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe. Archives of Osteoporosis. 17(1). 20–20. 4 indexed citations

McCloskey, Eugène, Mark Blagden, Bernard Cortet, et al.. (2020). The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporosis International. 32(2). 251–259. 95 indexed citations

McCormack, Terry, Ricardo Dent, & Mark Blagden. (2016). Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. International Journal of Clinical Practice. 70(11). 886–897. 25 indexed citations

Stroes, E.S.G., J Robinson, Frederick J. Raal, et al.. (2015). CLINICAL EQUIVALENCE OF EVOLOCUMAB AMONG PATIENT SUBGROUPS IN PROFICIO: A POOLED ANALYSIS OF 3146 PATIENTS FROM PHASE 3 STUDIES. Canadian Journal of Cardiology. 31(10). S300–S301. 4 indexed citations

Blagden, Mark, et al.. (2014). Long‐term evaluation of combined prolonged‐release oxycodone and naloxone in patients with moderate‐to‐severe chronic pain: pooled analysis of extension phases of two Phase III trials. Neurogastroenterology & Motility. 26(12). 1792–1801. 30 indexed citations

Löwenstein, O., Petra Leyendecker, Eberhard A. Lux, et al.. (2010). Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. PubMed. 10(1). 12–12. 65 indexed citations

O’Connor, Brian, S. Kilfeather, David W. Cheung, et al.. (2010). Efficacy and safety of ciclesonide in patients with severe asthma: a 12-week, double-blind, randomized, parallel-group study with long-term (1-year) follow-up. Expert Opinion on Pharmacotherapy. 11(17). 2791–2803. 7 indexed citations

Blagden, Mark, et al.. (2007). Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Current Medical Research and Opinion. 23(4). 767–775. 22 indexed citations

Blagden, Mark, et al.. (2002). MULTIDOSE FLURBIPROFEN 8.75 MG LOZENGES IN THE TREATMENT OF SORE THROAT: A RANDOMISED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY IN UK GENERAL PRACTICE CENTRES. International Journal of Clinical Practice. 56(2). 95–100. 33 indexed citations

10.

Kasper, Siegfried, Mark Blagden, A. Veerman, et al.. (2002). A placebo-controlled study of pregabalin and venlafaxine treatment of GAD. European Neuropsychopharmacology. 12. 341–342. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact